Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have been given an average rating of “Moderate Buy” by the five research firms that are covering the company, MarketBeat ...

Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Hold to Buy. Analyst Price Forecast Suggests 29.26% Upside As of December 23, ...

Check the time stamp on this data. Updated AI-Generated Signals for Collegium Pharmaceutical Inc. (COLL) available here: COLL ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

Collegium Pharmaceutical forecasts 2025 product revenues of $735-$750 million, with adjusted EBITDA of $435-$450 million. Collegium Pharmaceutical, Inc. has provided its financial guidance for ...

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) recently disclosed its full-year revenue, adjusted operating expense, and adjusted EBITDA guidance for 2025 in a press release on January 8 ...

STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with a price target of $50.00. Discover outperforming ...

Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with a focus on Jornay PM expected to exceed $135 million in net revenue.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...